- Medtronic adjusted its full-year EPS forecast slightly upward to a range of $5.62 to $5.66 from a previous outlook of $5.60 to $5.66.
- The company expects organic revenue growth of about 5.5%, up from an earlier forecast of 5%.
- In the second quarter, adjusted EPS grew to $1.36 from $1.26 year-over-year, surpassing estimates of $1.32.
- Second-quarter revenue reached $8.96 billion, a 6.6% year-over-year increase, beating the expected $8.87 billion.
- Cardiovascular revenue rose 11% year-over-year to $3.44 billion, exceeding the estimate of $3.36 billion.
- Medical Surgical revenue increased by 2% year-over-year to $2.17 billion, slightly below the projected $2.18 billion.
- Neuroscience revenue went up by 4.5% year-over-year, reaching $2.56 billion, in line with the estimate of $2.55 billion.
- Diabetes revenue grew by 10% year-over-year to $757 million, topping the forecast of $748.7 million.
- The adjusted operating margin fell slightly to 24.1% from 24.3% year-over-year, just below the expected 24.3%.
- Guidance reflects potential tariff impacts amounting to about $185 million, consistent with previous guidance.
- Excluding these tariff effects, the FY26 adjusted EPS is anticipated to grow by approximately 4.5%.
- Medtronic CFO Thierry Piéton highlighted efficiency improvements in gross margin, increased R&D investments, and strategic enhancements in sales and marketing initiatives.
- The company revised its full-year revenue and EPS guidance based on robust first-half performance and confidence in accelerating revenue growth.
Medtronic Plc on Smartkarma
Analysts on Smartkarma, such as Baptista Research, are closely covering Medtronic Plc, a leading healthcare technology company. In a recent report titled “Medtronic plc: Why Its Innovations in Diabetes Management Hold The Key To Its Future!“, Baptista Research highlighted Medtronic’s steady performance in the first quarter of fiscal year 2026. With mid-single-digit organic revenue growth and exceeding adjusted earnings per share expectations, Medtronic showcased consistency and effective cost management strategies.
Another report by Baptista Research titled “Medtronic Doubles Down on Innovation as Cardiovascular Tech Takes Center Stage!” emphasized the robust finish of Medtronic’s fourth-quarter results for fiscal year 2025. Medtronic experienced impressive growth across its cardiovascular, neuromodulation, and diabetes segments, driven by innovations in pulse field ablation and cardiac solutions. This positive momentum underscores the effectiveness of Medtronic’s innovation-centric strategy, as highlighted by independent analysts on Smartkarma like Garvit Bhandari.
A look at Medtronic Plc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Medtronic Plc, a global leader in developing therapeutic and diagnostic medical products, has received favorable Smartkarma Smart Scores indicating a positive long-term outlook. With a solid score of 4 in Dividend and Momentum, the company demonstrates strength in providing consistent dividends to investors and displaying strong market momentum. Additionally, scoring 3 in Value, Growth, and Resilience, Medtronic shows a good balance of being fairly valued, having room for growth, and being able to withstand market challenges. This indicates a promising future for Medtronic in terms of financial performance and stock stability.
Medtronic, PLC is known for its wide range of medical products catering to various health conditions including heart management, pain relief, and movement disorders. With a focus on innovations in bradycardia pacing, tachyarrhythmia management, and more, Medtronic has established itself as a key player in the global healthcare industry. The company’s strong presence in both developed and emerging markets reflects its commitment to providing quality medical solutions worldwide. Investors can be optimistic about Medtronic’s future growth potential and resilience in navigating market challenges based on its recent Smart Scores evaluations.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
